Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.